Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Heron Therapeutics Inc HRTX

Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and... see more

NDAQ:HRTX - Post Discussion

Heron Therapeutics Inc > Premarket Heats Up For This Biotech Before Opening Bell
View:
Post by whytestocks on Jan 24, 2024 10:30am

Premarket Heats Up For This Biotech Before Opening Bell

JUST IN: $HRTX Premarket Heats Up For This Biotech Before Opening Bell2024-01-24 09:37:29 ET A California-based %Biotech company is turning heads on Wednesday morning after it was announced that the company received FDA approval for the supplemental new drug application for %Zynrelef to include additional orthopedic and soft tissue procedures, accordi...HRTX - Premarket Heats Up For This Biotech Before Opening Bell
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities